Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study)

Kazuko Yamamoto, Naoki Iwanaga, Asuka Umemura, Toyomitsu Sawai, Makoto Sumiyoshi, Kohji Hashiguchi, Yusuke Mori, Hiroshi Ishii, Yoji Futsuki, Maiko Kiyohara, Kenji Ota, Kosuke Kosai, Daisuke Sasaki, Yuki Takamatsu, Shingo Inoue, Kouichi Morita, Shin Tsutsui, Kazuto Ashizawa, Takahiro Takazono, Noriho Sakamoto, Naoki Hosogaya, Masato Tashiro, Takeshi Tanaka, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae

Therapeutic Advances in Infectious Disease

Published online on March 15, 2026

Abstract

Therapeutic Advances in Infectious Disease, Volume 13, January-December 2026.
Background:Coronavirus disease 2019 (COVID-19) remains an epidemic worldwide, and long COVID is a major social concern. Therapeutic options for relieving symptoms of COVID-19 pneumonia are limited. Clarithromycin (CAM), a macrolide antimicrobial, also ...